G Cohen

Publications (3)6.62 Total impact

• Article: Systemic absorption of lidocaine after topical application for the treatment of oral mucositis in bone marrow transplantation patients.

  S Elad, G Cohen, E Zylber-Katz, M Findler, D Galili, A A Garfunkel, R Or
  [show abstract] [hide abstract]
  ABSTRACT: This paper evaluates lidocaine absorption via oral mucosa following its topical application for symptomatic treatment of bone marrow transplantation (BMT)-induced oral mucositis. Five patients with high-grade oral mucositis after allogeneic BMT were entered consecutively into the study. Five healthy individuals served as controls. All 10 participants rinsed their mouth with 5 ml of a 2% lidocaine solution for 1 min, after which they expectorated the liquid. Blood samples were drawn at 1, 5, 10, 20, 30 and 60 min after rinsing and centrifuged. Plasma lidocaine levels were measured by fluorescence polarization immunoassay. In the BMT patients, plasma lidocaine levels were lower than the therapeutic range of this drug (0.2 microg/ml vs 1.5-5.5 microg/ml), while in the controls no detectable lidocaine levels were noted. The data from this preliminary study indicate that lidocaine prescribed as an anesthetic mouthwash in BMT patients with oral mucositis results in minor systemic absorption of the drug.
  Journal of Oral Pathology and Medicine 05/1999; 28(4):170-2. · 1.63 Impact Factor
• Article: The use of tretinoin as oral mucositis prophylaxis in bone marrow transplantation patients: a preliminary study.

  G Cohen, S Elad, R Or, D Galili, A A Garfunkel
  [show abstract] [hide abstract]
  ABSTRACT: The examination of prophylactic efficacy of tretinoin on oral mucositis, post bone marrow transplantation (BMT). The study population consisted of 11 patients undergoing BMT. Six tretinoin topically-treated patients (0.25 mg daily of 0.1% tretinoin cream) were matched with five non-treated control patients comparing mucositis severity, duration and analgetic (morphine) requirements. Concomitant follow-up included conditioning parameters associated with mucositis and engraftment. The mean of oral mucositis peak scores was significantly lower in the tretinoin-treated patients vs the non-treated patients (score 1.5 vs 3.6; P < 0.02). In the majority of cases the duration of the most severe phase of oral mucositis was shorter in the tretinoin-treated group as compared with the control. Only one patient in the experimental group required morphine analgesics compared with four patients in the control group. This preliminary study indicates that the severity of oral mucositis, both objective and subjective, in BMT patients may be reduced by 0.1% topical tretinoin cream, 0.25 mg, administered daily from the beginning of the BMT conditioning regimen until marrow engraftment.
  Oral Diseases 12/1997; 3(4):243-6. · 2.49 Impact Factor
• Article: The use of tretinoin as oral mucositis prophylaxis in bone marrow transplantation patients: a preliminary study

  G. Cohen, S. Elad, R. Or, D. Galili, A.A. Garfunkel
  [show abstract] [hide abstract]
  ABSTRACT: OBJECTIVE: The examination of prophylactic efficacy of tretinoin on oral mucositis, post bone marrow transplantation (BMT).PATIENTS AND METHODS: The study population consisted of 11 patients undergoing BMT.Six tretinoin topically-treated patients (0.25 mg daily of 0.1 % tretinoin cream) were matched with five non-treated control patients comparing mucositis severity, duration and analgetic (morphine) requirementS. Concomitant follow-up included conditioning parameters associated with mucositis and engraftment.RESULTS: The mean of oral mucositis peak scores was significantly lower in the tretinoin-treated patients vs the non-treated patients (score 1.5 vs 3.6; P < 0.02). In the majority of cases the duration of the most severe phase of oral mucositis was shorter in the tretinoin-treated group as compared with the control. Only one patient in the experimental group required morphine analgesics compared with four patients in the control group.CONCLUSIONS: This preliminary study indicates that the severity of oral mucositis, both objective and subjective, in BMT patients may be reduced by 0.1% topical tretinoin cream, 0.25 mg, administered daily from the beginning of the BMT conditioning regimen until marrow engraftment.
  Oral Diseases 06/1997; 3(4):243 - 246. · 2.49 Impact Factor